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Recent scientific advances and new technological developments, most notably the advent 
of bio-informatics, have led to the emergence of genetic databases with particular 
characteristics and structures. Paralleling these developments, there has been a 
proliferation of ethical and legal texts aimed at the regulation of this new form of genetic 
database.* 
 
 
‘Database’ can be defined as a collection of 
data which is organized, prioritized and 
available for consultation, the content of 
which can evolve by the addition of updated 
information, and which, in this day and age, 
is always computerized, according to a 
variety of structures. In practice, the term 
‘database’ refers to the data processing 
structure as well as the relationship 
between different types of data, the method 
of data entry, updating and filing, the 
contents themselves and the request 
system enabling consultation. The terms 
“databank” and “biobank” are often used 
interchangeably, highlighting the notion that 
these databases are providing a service. 
With respect to biological samples and 
data, two trends are evident. The first 
 
makes a distinction between the physical 
biological samples themselves which, 
together, constitute a collection, and the 
database made up of the information 
derived from these samples and allowing for 
their characterization. The second trend, 
which currently predominates in the world of 
genomics, uses the term ‘database’ to 
denote the physical samples as well as the 
information derived there from. This is the 
position adopted by UNESCO in its 
International Declaration on Human Genetic 
Data.1  
 
 Genetic data bases, traditionally 
considered a component of specific 
research projects or limited to the study of a 
restricted number of samples, are now 
more and more frequently established or 
developed at the level of whole populations 
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or communities. Consider, for example, the 
Estonian Genome Project2 (Estonia), the 
UK Biobank3 (United Kingdom), 
CARTaGENE4 (Quebec), or, at the 
international level, GenomEUtwin5 which 
proposes a cross-border study including 
eight countries.6  
 
These projects contemplate the 
study of hundreds of thousands of 
individuals and propose varied methods for 
participant recruitment and follow up. Due 
to the proliferation of such databases, the 
question of international coordination and 
organization arises, both on a scientific and 
ethical level. International projects such as 
the “Public Population Project in Genomics” 
consortium (P3G)7 have been put in place 
to deal with these new issues. Specifically, 
the P3G consortium aims to create a 
“knowledgebase”, a virtual observatory 
where scientific, ethical, legal and social 
tools developed and used by its various 
members are made available to all. In the 
process, it hopes to generate a certain 
harmonization, if this is possible and 
scientifically desirable. 
  
Populational genetic databases 
have specific characteristics. They are a 
testimony to the shift from local projects to 
national or international projects which has 
been engendered by the progressive 
dissolution of borders and the strengthening 
of the global dimension of research. 
Designed as veritable research 
infrastructures rather than as projects 
aimed at the study of a particular illness or 
genetic characteristic, they constitute 
strategic resources allowing for the conduct 
of research involving stored data originating 
from populations or communities which may 
be separated by distance or time. The 
resulting research leads to the production of 
new data which may in turn enrich the initial 
database. As platforms for research, they 
are established over a prolonged period 
spanning several generations; the 
anticipated results and benefits are 
therefore considered over the long term. 
  
These databases have become 
essential with the development of 
population genetics. Population-based 
genetic study has been defined in 
UNESCO’s International Declaration on 
Human Genetic Data as “[a] study which 
aims at understanding the nature and 
extent of genetic variation among a 
population or individuals within a group or 
between individuals across different 
groups.”8  
 
This type of study is designed to 
allow for the analysis of the genetic 
composition of populations and factors 
affecting this composition, as well as factors 
underlying its evolution and adaptation, in 
particular, natural selection, mutations and 
migrations. The knowledge derived from 
such studies are an essential pre-requisite 
for the understanding of common diseases 
which are usually multi-factorial, that is to 
say resulting from the interaction of multiple 
parts of the individual’s genome with each 
other and with the environment. In order to 
understand the complexities of these 
common diseases it is necessary to have 
recourse to large collections of samples 
derived from individuals from one or several 
communities or populations, both sick and 
healthy. In the long term, understanding 
these common diseases will open up the 
possibility of prediction and prevention from 
the perspective of public health.  
 
As summarized by the  Bioethics 
Advisory Committee of the Israel Academy 
of Sciences and Humanities: 
 
 3. (…) By analyzing the polymorphisms 
throughout the entire genome, correlations 
with occurrence of disease can be 
established by the technique of genetic 
association analysis.  
 4. Because these comparisons are statistical in 
nature, in order to be meaningful, they must 
be performed on a large scale (many 
thousands of samples). They may also be 
most powerful when carried out in cohorts of 
patients and healthy controls having a 
common ethnic origin so as to minimize 
unrelated variations. Hence, the need to 
establish population-based large-scale DNA 
collections. (…)9
 
 Many of the characteristics 
particular to populational databases raise 
specific scientific, legal, ethical and social 
questions which challenge the adequacy of 
the ethical and legal norms traditionally 
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applied to research. Some of these 
characteristics include the magnitude of the 
projects, the fact that the precise nature of 
the research that could be conducted using 
the database is not yet known, the absence 
of direct benefits (the benefits are 
necessarily long term), and the duration of 
the projects. Other issues relate to the 
involvement of the populations or 
communities studied, the possibility of 
stigmatization that could arise from the use 
of the results, the necessity of exchange and 
transfer of information, the possible role 
played by private industry, and the private or 
private-public financing of these platforms. 
  
Due to these special considerations, 
it becomes necessary to inquire whether 
there are texts that seek to regulate such 
matters at the international, regional or 
national level. If such documents exist, it is 
necessary to determine if there are common 
principles that emerge or if harmonization or 
the elaboration of ‘minimum standards’ is 
possible or desirable in light of the need to 
respect cultural diversity in approaching the 
problem. If, on the other hand, no specific 
text has been adopted, it will come down to 
the existence of an ethical debate and the 
issues and conclusions emerging there 
from.  
 
Finally, whether or not specific rules 
have been adopted, the crucial question 
becomes whether it would be appropriate to 
adopt norms specifically tailored to 
populational genetic databases – an 
approach inspired by “genetic 
exceptionalism”.10 We will therefore 
examine the existing normative context (I.) 
before proceeding to an analysis of the 
normative issues associated with 
populational genetic databases (II.).  
 
I.  Populational Genetic Databases : 
Existing Norms 
 
The current trend is towards a 
proliferation of levels of norms and a 
specialization of national and international 
norms (from guiding principles for genetic 
research to the administration of 
populational databases). 
 
a. The International and Regional 
Context (Table 1) 
  
 At the international and regional 
level, we are witnessing a proliferation and 
specialization of norms. Some common 
principles can be extracted from these 
norms. 
 
Numerous texts have been adopted over 
the last few years, but their field of 
application is noticeably becoming more 
and more specific. Thus, we have moved 
from general principles relating to 
biomedical research (CIOMS11, CE12), to 
norms pertaining to medical databases 
(AMS)13, to the collection, use and storage 
of proteomic and genetic data (UNESCO14, 
ESHG15) and/or the administration of 
genetic (OMS)16 or genomic (HUGO)17 
databases.  
  
 These norms, which provide 
guidance to national jurisdictions in their 
normative approach to these matters, re-
iterate and re-affirm the principles stated in 
UNESCO’s Universal Declaration on the 
Human Genome and Human Rights.18 
These principles emphasize respect for 
human dignity, solidarity, equality and 
justice as well as responsibility and 
transparency in the conduct of research.  
 
The first provision of UNESCO’s 
International Declaration on Human Genetic 
Data reads as follows: 
 
The aims of this Declaration are: to ensure 
the respect of human dignity and protection 
of human rights and fundamental freedoms 
in the collection, processing, use and 
storage of human genetic data, human 
proteomic data and of the biological samples 
from which they are derived (…) in keeping 
with the requirements of equality, justice and 
solidarity, while giving due consideration to 
freedom of thought and expression, including 
freedom of research (…)19
 
 Although these texts re-affirm the 
traditional fundamental principles, they also 
adapt them to new scientific realities, 
notably those related to genetics. In this 
respect, genetic data or databases are 
evaluated both for their acceptability and 
value at the individual level as well as at the 
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familial and communal levels. The 
identification and affirmation of these special 
considerations has led to the emergence of 
a variety of new concepts. For example, the 
right to know and the right not to know have 
progressively been established. Although 
their scope remains uncertain, these rights 
benefit not only the patient but also those 
affected by genetic risks arising, for 
example, from an obligation to disclose 
certain information in particular 
circumstances. Similarly, because of the 
‘sensitive’ and ‘revealing’ nature of genetic 
information, the protection of participants 
against third party access to identifying 
information (insurers, employers, public 
services, institutions) and against 
discrimination or stigmatization20 are also 
re-enforced.  
 
In the more specific context of 
databases - considered a form of ‘global 
public good’ - the public has been given, if 
not an active role, then at least a right to 
information and consultation as well as a 
right to receive the shared benefits of 
research. Finally, special attention is given 
to vulnerable persons. The rules concerning 
their participation have been noticeably 
modified: although this participation is still 
well circumscribed, greater recognition is 
given to their personal autonomy. 
 
 All of these texts attempt to find an 
adequate balance between the protection of 
the individual as the very basis of society 
(e.g. limitations on purposes for which 
research may be undertaken, protection of 
individuals, communities and populations) 
and the necessary progression of research 
for the benefit of society as a whole. This 
tension underlies all attempts at regulation 
of research involving humans, but in this 
context takes on greater magnitude given 
the length of the anticipated projects and 
the inevitable lack of precision that exists at 
the time subjects consent to participate.  
  
b. The National Context : 
Inconsistencies 
 
i. Legislation Specific to 
Biobanks (Table 2) 
  
 In light of the emergence and 
proliferation of populational database 
projects, some countries have decided to 
adopt specific legislation aimed at their 
regulation. These laws operate in 
conjunction with pre-existing privacy 
legislation and either take the form of 
regulations applicable to all genetic 
database projects, or strive to control, 
supervise and provide a framework for a 
specific national project. Estonia and 
Lithuania enacted the Human Genes 
Research Act21and the Human Genome 
Research Law22, respectively, with the goal 
of establishing and supervising their 
national biobank project. This course of 
action would appear to have been 
motivated by the inadequacy of existing 
norms, an inclination to support the thesis 
whereby genetic data, and a fortiori genetic 
research, require special attention and can 
be distinguished from traditional medical 
data and research, and the desire to ensure 
democratic legitimacy for their project. 
 
 Although the adoption of specific 
laws responds to particular needs and 
allows for legal clarity and certainty, it also 
raises a number of problems. Effectively, in 
the case of regulations applicable to all 
databases regardless of their of nature or 
date of establishment, there may be 
conflicts between the newly delineated rules 
and the rules in force at the time the 
biobank was established. For example, if 
the new law requires that specific consent 
be obtained for participation in research 
involving the creation of a biobank, 
previously amassed collections obtained on 
the basis of general consent will no longer 
be legitimate and studies using that data 
will have to be interrupted.  
 
Furthermore, by creating different 
standards depending on whether the 
research is purely medical, including 
genetic research for which no collection is 
created and which does not serve to 
establish a populational database, the 
promulgation of specific laws could lead to 
a genetic exceptionalism which, to date, 
remains unfounded. In France, a legislative 
text introduced in 199623 instituting a 
specific regime for genetically based 
collections demonstrated a lack of 
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coherence and sparked confusion. In 2004, 
24  in response to the criticisms that this 
specific regime provoked, the legislator re-
established a unified and homogeneous 
system covering all collections built up in 
the context of biomedical research.  
  
ii. Non-Specific Legislation and 
Ethical Debate (Table 3) 
 
 A number of national jurisdictions do 
not have a text specific to populational 
databases. These databases are therefore 
governed by a group of rules found in 
various law. This state of affairs sometimes 
gives rise to confusion, conflicting rules, or 
insufficiency and undue complexity by 
reason of the co-existence of several 
systems or regimes. Notwithstanding this 
legislative silence, the ‘biobank’ 
phenomenon has not only been the subject 
of ethical debate, but national database 
projects have also come to the fore through 
a process of self-regulation.  
  
 The ethical debate taking place in 
numerous countries has generally resulted 
in a recognition of the specific 
considerations associated with populational 
datases, specifically with respect to their 
nature (research infra-structure), the 
impossibility of anticipating all the research 
studies that might be conducted based on 
the collected data, and the indeterminate 
and indeterminable duration of storage. 
Existing legislative frameworks being 
inadequate to take all of these particularities 
into account, the need for more precise 
national rules has become apparent. As 
noted by the Israeli Bioethics Advisory 
Committee: 
  
Considerable organization and financial 
means are required for assembling large 
scale collections of DNA samples and 
deriving databases of genetic information 
linked to health records of individuals. The 
magnitude of the operation together with the 
specific ethical issues mentioned above - 
particularly regarding commercial initiatives - 
underscore the need for national guidance. 
Clearly there should be nationwide moral (if 
not financial) support for such projects.25  
 
 However, for the sake of coherence 
and simplification, and in order to clarify 
overlapping rules, it is generally proposed 
that existing texts be amended as 
necessary instead of establishing a specific 
legal framework. While awaiting these 
modifications, some jurisdictions have 
mitigated the absence of legislation by 
elaborating ethical norms applicable to 
biobanks.26
 
 Furthermore, in their desire to create 
populational data banks, researchers have 
developed their scientific protocol, ethical 
framework and project guidelines in 
collaboration with the community or 
population studied, health professionals, 
ethicists, lawyers and sociologists (self-
regulation). These developments have 
resulted in reports, commentaries, 
workshops, forums (etc.) which are 
generally available on their website (see 
e.g. CART@GENE & UK Biobank, supra) 
and which convey a real concern for 
transparency. 
  
II. Populational Genetic Databanks : 
Normative Issues  
 
a. The Challenge of Harmonization 
 
 The proliferation and 
specialization of laws leads to a 
multiplication of standards and terminology. 
This creates difficulties for research in an 
era where projects are increasingly 
international in scope and where there is a 
need for transfer and exchange of data. The 
elaboration of an international nomenclature 
is therefore becoming essential. A case in 
point is the multiplication of terms used to 
describe the degree of protection of data 
used for research.  
Traditionally terms such as 
‘anonymous’, ‘anonymized’, ‘coded’, 
‘double-coded’, and ‘identifiable’ have been 
used. Recent normative documents have 
introduced new categories which have little 
or no similarity with the traditional 
categories, thereby creating needless 
complexity and making interpretation more 
difficult. Thus, terms such as ‘data 
irretrievably unlinked to an identifiable 
person’ (UNESCO art. 2), ‘unlinked 
anonymized’ (ESHG), and ‘proportional or 
reasonable anonymity’ (UNESCO 4.2) 
reformulate the notions of ‘anonymized’, 
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‘double-coded’, or ‘coded’, as the case may 
be. 27
 
 At the international level, 
harmonization has therefore become a 
priority, although it poses significant 
challenges. As the Council for International 
Organizations of Medical Sciences has 
remarked:  
 
The challenge to international research 
ethics is to apply universal ethical principles 
to biomedical research in a multicultural 
world with a multiplicity of health-care 
systems and considerable variationin 
standards of health care. 28
 
b. Despite Emerging Consensus, 
Controversy Persists (Table 4) 
 
 Harmonization seems to be 
facilitated by the emergence of a consensus 
with respect to certain concepts or rules, 
however, many of the details remain 
controversial. 
 
i.  Consent 
 
 The traditional mechanisms of 
consent are being modified in order to 
accommodate the special characteristics of 
databases or ‘biobanks’. Because of the 
impossibility of foreseeing all the possible 
future uses of the data from the start, 
specific consent does not seem adequate. 
 However, the very nature of the 
consent required is a subject of debate: 
some favor general consent or consent with 
a variety of options while others speak of a 
‘blanket consent’ which approximates 
implied consent.  
 
ii.  Privacy/Confidentiality 
 
 It is recognized that the degree of 
protection of data (anonymous, 
anonymized, double-coded, coded, 
identifiable) is closely tied to questions of 
withdrawal from a research project, 
dissemination of results to participants 
generally or individually, follow up of 
participants, and third party access to 
research data. Unlinked treatment of these 
elements can lead to contradictions or 
practical impossibilities. There is a wide 
spectrum ranging from identifying or 
personal data (for which there is significant 
protection, very limited access, and the 
possibility of withdrawal) to anonymized 
data (for which there is free access for 
research purposes, no possibility of re-
contacting participants, and no possibility of 
withdrawal from the project). 
  
 However, when considering the 
confidentiality of data, problems of taxonomy 
arise. As mentioned above, the vocabulary 
used to describe the degree of protection of 
data is extremely varied, with different terms 
being used to describe the same realities 
and vice-versa. The criteria used to 
determine an adequate degree of protection 
are also problematic. Coding, double-
coding, and anonymization are not 
established in a homogeneous fashion. And 
since anonymization is only well suited to a 
restricted number of projects due to its 
inherent limitations, the protection of data 
will vary according to the questions and 
norms at issue. 
  
 Finally, access to research data is 
another big issue. The policy on access 
varies drastically from project to project, 
even within the same legislative context or 
ethical framework. The precise definition of 
‘who may have access and under what 
conditions?’ is a source of debate both with 
respect to its underlying principles and with 
respect to the practical implementation of 
the conditions of access or protection. In this 
manner, questions of family or third party 
access often lead to the decision to create 
different categories of data within the same 
biobank, which in turn complicates its 
management. 
iii.  Dissemination of Results / 
Participant Information 
  
 The guiding principle for the 
dissemination of results is one of 
comprehensive information prior to any 
participation in a project conducted on a 
populational scale.  
 
 However, the issue of ongoing 
participant information over the course of the 
project raises certain difficulties. The right to 
know and the right not to know take on new 
complexities in the context of populational 
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databanks due to the diversity of the data 
produced or processed; this data could 
simply be of statistical interest without any 
useful individual elements, or it could be of 
clinical interest with the possible need for 
genetic counseling and careful 
interpretation. It is worth noting that 
individual research results derived from 
populational databanks are often of no 
clinical interest and can lead to 
misinterpretations due to the fact that they 
are based on incomplete information (most 
often biobanks are not accompanied by 
access to the participant’s complete medical 
record). In addition, if individual results are 
provided to participants, there may be a 
need for genetic counseling since a 
researcher cannot be left to interpret the 
results and communicate them to the 
participant without the accompaniment of 
adequate counseling.  
 
But genetic counseling requires 
financing and infrastructure that are not 
anticipated in the research context; it also 
seems difficult to apply the rules followed in 
the clinical context to the domain of 
research. In many cases, then, individual 
reporting is not planned for since the results 
are considered to be of purely scientific 
interest (e.g. the UK Biobank which is 
developing a research infrastructure)29; in 
other cases normative texts will prescribe 
that these individual results must be 
provided to participants (e.g. Estonia has 
adopted a doctor-patient model)30. 
 
iv. Risks / Stigmatization 
 
 Because of the sensitive nature of 
certain genetic data, it is recognized that 
their treatment and study at the level of 
whole populations or communities can entail 
risks of discrimination or stigmatization. 
These risks must be recognized, both with 
respect to recruitment and interpretation of 
results, by properly informing participants 
and by taking action to avoid or minimize 
their occurrence. 
 
However, informing participants of 
the risks of stigmatization combined with 
‘misinformation’ on the nature of biobanks 
can have a negative impact on recruitment 
and can even introduce biases. Providing 
participants with too many details on the 
remote possibility of stigmatization may 
alarm them and lead them to question the 
legitimacy and true nature of the proposed 
research. Because the probability of 
discriminatory events cannot be predicted 
with any degree of certainty, it becomes 
impossible to duly inform. In this case, 
transparency leads to imprecision and may 
even breed skepticism. 
 
v.  Governance and Monitoring 
 
 Well recognized guiding principles 
include the need for adequate ethical and 
scientific supervision from the moment a 
database is created, the establishment of 
control mechanisms for the entire duration of 
research projects (ongoing monitoring), and 
the independence of supervising institutions. 
 
 However, ethical supervision of 
international projects involving multiple 
countries raises a number of unresolved 
questions. The nature of this control and the 
bureaucratization of the process remain 
acute problems. There has been little work 
and little documentation concerning the 
question of which body will supervise multi-
country projects and the possibility of an 
eventual gradation of controls at different 
levels. 
   
 Governance is another thorny 
question. How should powers and counter-
powers be established with a view to 
ensuring transparency and responsible 
conduct of research? Numerous texts 
(especially those specific to biobanks) 
discuss this issue but remain vague as to 
the governance and control of projects once 
approved. Governing bodies need 
independence and real powers in order to 
ensure that ethical, legal and scientific 
norms are respected and uniformly applied. 
  
 
vi.  Public Involvement : Public 
Confidence as a Foundation 
 
More and more, the public is 
recognized as an active participant in the 
elaboration and development of large-scale 
projects. The initiation, promotion and 
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reinforcement of dialogue between 
professionals and the public is gaining force 
not only during the establishment of all new 
populational databases, but also during the 
development of the legal and ethical 
framework and implementation of the 
project.  
 
However, on the one hand, the 
definition of this ‘public’ is subject to dispute 
and, on the other hand, the nature of their 
involvement is unclear. The need to inform, 
include, and obtain the consent of the 
community or the population are put forward 
without specifying the character of this 
involvement.  
 
vii. Commercial Aspects 
  
 Finally, the need to elaborate a 
policy on the sharing or distribution of the 
profits or benefits and the acknowledgement 
of the commercial aspects of databases are 
recognized. 
 
 In practice, even greater 
uncertainties arise here with respect to 
setting up guiding principles and ensuring 
transparency; this is due to the variable and 
changing nature of project financing (public 
projects vs private or semi-private projects) 
and to the still ambiguous status of genetic 
material for which numerous elements must 
be taken into account (property rights, 
remuneration or compensation of 
participants, financial gains, other types of 
gain, beneficiaries).  The issue of direct 
participation of private companies in these 
projects, even if relatively rare, remains 
controversial since biobanks commingle 
notions of property shared by all of humanity 
with populational and individual 
considerations.  
  
Conclusion 
 
Certain issues dominate the horizon 
explored here. First of all, there is a current 
trend towards the proliferation of texts at the 
international, regional and national levels. 
Secondly, a degree of confusion and 
questioning as to the desirability of 
developing specific texts is becoming 
apparent.  
 
Our review demonstrates that a 
harmonization of principles and vocabulary 
at the international level is becoming 
crucial. At the national level, our review 
reveals the need to amend existing 
normative frameworks in order to 
encompass characteristics common to all 
databases, leaving particular projects with 
the responsibility for self-regulation of 
particular facets of their research, yet 
putting in place mechanisms to ensure that 
this self-regulation is done in a responsible 
and transparent manner.  
 
In elaborating such a framework, 
two  pitfalls must be avoided: genetic 
exceptionalism and a purely occidental, 
Anglo-Saxon or Northern European 
approach to research and its regulation. 
Genetic exceptionalism could spring from 
the heightened scientific attention being 
given to genetics and genomics and may, in 
the long run lead, to a reduction of the 
individual to his/her genetic cartography by 
making a distinction between genetic data 
and health data, even in the absence of any 
justification for doing so. Recommendation 
3 of the multidisciplinary Expert Group 
invited by the European Commission to look 
at the issue of genetic tests could equally 
apply to populational databanks; it reads as 
follows: 
 
‘Genetic exceptionalism’ should be avoided, 
internationally, in the context of the EU and 
at the level of its Member States. However, 
the public perception that genetic testing is 
different [we will substitute traditional or 
populational genetic databanks] needs to be 
acknowledged and addressed.31  
 
Yet international texts are 
ambiguous in this respect. For example, 
UNESCO’s International Declaration on 
Human Genetic Data32 is ambiguous in its 
article 3 (a person’s identity should not be 
reduced to genetic characteristics) and 
article 7 (special status of genetic data). 
Furthermore, certain national texts consider 
genetic data and databases as a separate 
category rather than as a sub-category of 
medical data. A purely occidental, Anglo-
Saxon or Northern European approach to 
research and its regulation is frequently 
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adopted, even though exchange is crucial in 
this area. 
 
These pitfalls aside, distinctions 
must be made between the international, 
national and project levels when 
considering populational databanks and 
their regulation, since each raises different 
issues. 
 
 At the international level, in light 
of the internationalization of research and 
the increase in data and sample transfer and 
exchange, a harmonization of guiding 
principles and terminology is essential. First 
of all, the guiding principles must be 
distinguished from the specific rules. 
Specific rules cannot take into account the 
particularities of every national legal system 
since these follow different legal traditions.  
 
For example, the question of 
property rights in, control over, or non-
availability of one’s body receives different 
treatment in countries with a Common Law 
tradition as opposed to a Civil Law tradition, 
and therefore a consensus could not be 
reached. It is also important to be aware of 
cultural and religious diversity around the 
world and to seek to preserve this diversity 
by adapting the processes and rules. Thus, 
in the HapMap33 project, the involvement of 
the public and the nature of the consent 
process have been adapted to the different 
populations studied while maintaining a 
common framework.  Next, there must be an 
agreement as to terminology.  
 
Even though each international 
organization wishes to pronounce its own 
rules, it is necessary to avoid unnecessary 
terminological complexity which confuses 
researchers, ethicists, legal professionals 
and the public, and which requires 
interpretation and creates immaterial 
semantic debate. Transparence and clarity 
should be the guiding principles for all 
organizations. Finally, there is a need to 
ensure that all actors comply with these 
norms, including public and private financing 
bodies, researchers, professionals involved 
in research (ethicists, lawyers, sociologists, 
etc.), as well as populations and 
communities.   
 
Despite the existence of numerous 
declarations, guiding principles and codes 
dealing with the issue of genetic data, the 
changing conditions of genetic research call 
for the establishment of an international 
instrument that would enable states to agree 
on ethical principles, which they would then 
have to transpose into their national 
legislation.34  
 
At the national level, it is coherence 
that must be promoted. Existing legal 
frameworks must be amended in order to 
accommodate the particular features of 
populational databases, and ethics should 
serve as a guide to researchers. The 
modification of existing laws should not, 
however, translate into the creation of 
different legal categories, but rather should 
ensure increased protection for medical 
data. These amendments should not be 
done in haste and without long term vision 
since this would only provide specific 
answers to current problems. New problems 
may surface and legislative mechanisms, 
which are so heavy and difficult to change, 
lack the flexibility that may be required to 
resolve these problems. Coherence must be 
assured while avoiding too much 
bureaucratization of research and while 
building a dialogue between professionals 
and the population as a whole.  
 
 
Finally, states should endeavor to 
provide support for national projects by 
offering some degree of financing, thus 
guaranteeing a role for public authority. 
 
 
For the projects themselves, self-
regulation seems preferable to legislation 
specifically targeted at populational 
databases. As highlighted above, legislative 
mechanisms lack flexibility and the process 
for amending legislative rules is extremely 
slow. Self-regulation therefore offers greater 
flexibility. Where research involving the 
creation and use of research infrastructures 
(populational databanks) is only in its initial 
stages, this research must be preceded by a 
debate which includes the community or 
population as a whole; the process must 
also comply with international guiding 
principles.35  
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Likewise, effective involvement of 
research ethics committees in all stages of 
research will only evolve under conditions 
which guarantee their independence and the 
coherence of their evaluation (avoid too 
much bureaucratization), and which provide 
them with the powers necessary to carry out 
their mandate.  These two elements 
promote and are based on the principles of 
caution, transparency and responsibility. 
 
 Finally, at the international as well 
as the national and individual project level, 
prudence and openness are in order due to 
the difficulty of predicting all the problems 
that will be faced by ‘bankers’ who have 
established or are managing populational 
databases. Furthermore, in light of the 
uncertain long term scientific value of these 
banks as tools in achieving the desired 
goals, mechanisms must be put in place to 
evaluate the use of these research 
infrastructures and their impact on the 
progression of knowledge in genomics and 
their application in the domain of public 
health.36
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Table 1. International Instruments (2000-2004) 
International norms pertaining to biomedical research in general 
World Medical Association (WMA) 
 
 
Declaration of Helsinki, 1964, amended in 2000, 
clarification notes 2002 et 2004, 
http://www.wma.net/e/policy/b3.htm  (Date 
accessed : February 24, 2005) 
Council for International Organizations of 
Medical Sciences (CIOMS) 
International Ethical Guidelines for Biomedical 
Research Involving Human Subjects, Geneva, 
November 1, 2002, 
http://www.cioms.ch/frame_guidelines_nov
_2002.htm  (Date accessed : February 24, 2005) 
Council of Europe (CE)  Additional Protocol to the Convention on Human 
Rights and Biomedicine Concerning Biomedical 
Research, Strasbourg, June 30, 2004, opened for 
signature January 25, 2005 
http://www.coe.int/T/E/Legal_Affairs/Legal
_co-
operation/Bioethics/Activities/Biomedical_re
search/195%20Protocole%20recherche%20
biomedicale%20e.pdf   (Date accessed : February 
24, 2005) 
International norms specific to biobanks of human biological materials and/or (associated) data 
European Society of Human Genetics (ESHG)  Data Storage and DNA Banking for Biomedical 
Research: Technical, Ethical and Social Issues , 
November 2001, 
http://www.eshg.org/ESHGDNAbankingrec.
pdf (Date accessed : February 24, 2005) 
World Medical Association (WMA) The World Medical Association Declaration on Ethical 
Considerations Regarding Health Databases, 
Washington, October 6, 2002, 
http://www.wma.net/e/policy/d1.htm (Date 
accessed : February 24, 2005) 
Human Genome Organisation (HUGO)  Statement on Human Genomic Databases, London, 
December 2002, 
http://www.biol.tsukuba.ac.jp/~macer/HUG
OHGD.htm  (Date accessed : February 24, 2005) 
World Health Organization (OMS)- European 
Partnership on Patients’ Rights and Citizens’ 
Empowerment
Genetic Databases – Assessing the Benefits and the 
Impact on Human and Patient Rights, 2003, 
http://www.law.ed.ac.uk/ahrb/publications/
online/whofinalreport.pdf (Date accessed : 
February 24, 2005) 
United Nations Educational, Scientific and 
Cultural Organization (UNESCO) 
International Declaration on Human Genetic Data, 
Paris, October 16, 2003, 
http://portal.unesco.org/en/ev.php-
URL_ID=17720&URL_DO=DO_TOPIC&URL_
SECTION=201.html   (Date accessed : February 
24, 2005). 
European Union (1)  European Commission, Directorate-General for 
Research, Directorate C (Science and Society), Unit C3 
(Ethics and Science), 25 Recommendations on the 
Ethical, Legal and Social Implications of Genetic 
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Testing, May 2004, 
http://europa.eu.int/comm/research/confer
ences/2004/genetic/pdf/recommendations_
en.pdf  (Date accessed : February 24, 2005)
 
N.B. These recommendations were prepared by a 
multidisciplinary expert group consulted by the 
European Commission. Though this document 
focuses on genetic testing, several recommendations 
address human biological material collections and 
associated data specifically (see e.g. 
Recommendations 19, 20 and 21). Their base is 
detailed in a reportfrom the same  group  including a 
chapter on biobanks and were discussed at a 
Conference in May 2004. The report and the 
Conference proceedings are available at : 
http://europa.eu.int/comm/research/
conferences/2004/genetic/report_en.
htm (Date accessed April 15, 2005) 
 
 
(2) Directive 2004/23/EC of the European Parliament 
and of the Council of 31 March 2004 on setting 
standards of quality and safety for the donation, 
procurement, testing, processing, preservation, storage 
and distribution of human tissues and cells, Strasbourg, 
March 31, 2004, 
http://europa.eu.int/smartapi/cgi/sga_doc?
smartapi!celexapi!prod!CELEXnumdoc&lg=e
n&numdoc=32004L0023&model=guicheti
 (Date accessed : February 24, 2005)
Official Journal L 102, 07/04/2004 P. 0048 - 0058  
 
N.B. Though the scope of this directive is limited to  
therapeutic applications, the principles it lays down 
have implications for research. 
 
 
 
Table 2: National legislation specific to biological material 
and/or data collections (examples) 
 
Legislation regulating biobanking activities (general) 
 
Iceland 
 
(1) Act on Biobanks no. 110/2000, May 13, 2000, 
http://brunnur.stjr.is/interpro/htr/htr.nsf/printview/Act-biobanks (Date 
accessed: February 24, 2005) 
 
Art. 2 Scope 
This Act applies to the collection of biological samples, and their keeping, handling, 
utilisation and storage in biobanks. 
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This Act does not apply to temporary keeping of biological samples taken for purposes of 
clinical testing, treatment, or for specific study, provided such samples are destroyed when the 
tests, treatment or research are completed. Temporary keeping means storage for up to five 
years, unless the National Bioethics Committee authorises a longer period of storage. Should 
the long-term preservation of such samples be desired, they shall be stored in a biobank. 
 
The Act does not apply to the storage of gametes and embryos under the provisions of the Act 
on Artificial Procreation, to organs under the provisions of the Act on Organ Removal, or to 
bodily remains under the terms of the Natural Heritage Act”. 
 
Regulations on the Keeping and Utilisation of Biological Samples in Biobanks No 
134/2001, Reykjavik, February 6, 2001, 
http://brunnur.stjr.is/interpro/htr/htr.nsf/pages/lawsandregs0001 (Date 
accessed: February 24, 2005) 
 
Art. 1 Scope 
“These regulations apply to the collection of biological samples, their storage, handling, 
utilisation and preservation in biobanks.” 
 
 
Norway 
 
Act on Biobanks No 12, February 21, 2003, 
http://www.europa.eu.int/comm/research/biosociety/pdf/norwegian_act_b
iobanks.pdf (Date accessed: February 24, 2005) 
 
Para. 3 Scope 
“This Act applies to the collection, storage, processing an destruction of human biological 
material and information that forms part of a biobank [includes diagnostic, treatment and 
research biobanks, including the organization of these activities] 
(…) 
Biological material that is taken for the purpose of medical examination, diagnosis and 
treatment and that is destroyed shortly afterwards does not come within the scope of this Act.  
The Act nevertheless applies if such material is used for research purposes.” 
 
Legislation on biobanks established from samples collected as part of care 
 
Sweden 
 
Biobanks [Health Care] Act (2002:297), May 23, 2002, 
http://www.sweden.gov.se/content/1/c6/02/31/26/f69e36fd.pdf (Date 
accessed: February 24, 2005) 
 
Section 3 
“The Act applies to: 
1. Biobanks that are established in Sweden as part of a care’s provider’s medical activities, 
irrespective of where the material in the biobank is stored, and 
2. Tissue samples from a biobank as indicated in 1 that are released for storage and use on 
the premises of another care provider, an institution for research or diagnostics, a public 
research institution, a pharmaceutical company or other legal entity or other legal entity, 
and which after the release are traceable to the person or persons from whom they 
originate 
Relevant parts of the Act shall apply for tissue samples taken and collected for transplant 
purposes in accordance with the Transplants Act (1995:831). 
The Act does not apply to specimens that are routinely collected in the course of medical 
care for analysis, and which are solely intended to form the basis of a diagnosis and the 
ongoing care and treatment of the donor, and which are not stored for a long period.” 
 
(2005) vol. 3, no. 1, GenEdit, 1-13 
www.humgen.umontreal.ca/genedit 
Permission to reproduce granted if the source are correctly identified. ISSN 1718-9314 13
Legislation regulating population biobanks 
 
Estonia 
►The 
Estonian 
Gene Bank 
(Estonian 
Genome 
Project) 
 
Human Gene Research Act, 13 décembre 2000, 
http://www.legaltext.ee/text/en/X50010.htm (Date accessed: February 24, 2005) 
Para 1 Purpose and scope of application of Act 
(1) The objective of this Act are to regulate the establishment and maintenance of a Gene 
Bank, to organise the genetic research necessary therefor [sic], to ensure the voluntary nature 
of gene donation and the confidentiality of the identity of gene donors, and to protect persons 
from misuse of genetic data and from discrimination based on interpretation of the structure of 
their DNA and the genetic risks arising therefrom.(…) 
 
Latvia►The 
Unified 
Genome 
Database of 
the Latvian 
Population 
(Latvian 
Genome 
Project) 
 
 
Human Genome Research Law, July 3, 2002, 
http://bmc.biomed.lu.lv/gene/print/Human Genome Research Law, 
Latvia.doc (Unofficial translation by the Biomedical Research and Study Centre) (Date 
accessed: February 24, 2005) 
 
Section 2. Purpose and Scope of the Law 
 
(1) The purpose of the Law is to regulate the establishment and operation of a single genome 
database of the State population (hereinafter – genome database), the genetic research related 
thereto, to provide the voluntary nature and confidentiality of gene donation regarding the 
identity of gene donors, as well as to protect persons from misuse of genetic data and 
discrimination related to genetic data (…)” 
 
 
Table 3 : National ethical debate on biobanking activities : 
amendments to existing legal standards (examples) 
 
 Biobanking activities and ethics : debate and norms 
 
Canada / 
Québec 
 
1) Recommendations for the implementation of a framework for biobanking 
activities  (Québec) 
 
Commission de l’Éthique de la Science et de la Technologie, The Ethical Issues of 
Genetic Databases : Towards Democratic and Responsible Regulation : Position 
Statement- Summary and Recommendations, Sainte-Foy, December 16, 2002, 
http://www.ethique.gouv.qc.ca/eng/ftp/Avis10-02-03.pdf  (Date 
accessed: February 24, 2005) 
 
Recommendations, need for 
- Provide adequate financial support to Research Ethics Boards (REBs), training 
opportunities and certification to their members, as well as improve communication 
between REBs. Reflection on the role of REBs in the private sector to be continued. 
- Ensure for all population biobanks the participation of the Quebec population in the 
decision-making process 
- Promote biobanks’ social legitimacy and transparency 
- Strengthen  the protection of participants through carefully drafted informed consent 
procedures 
- Establish a registry under the responsibility of the public curator of research 
participants that are incompetent to provide an informed consent. 
- Remedy the shortcomings of current consent forms: consent (living and deceased 
individuals) and secondary uses  
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- Warrant the involvement of genetic counsellor in all stages of research projects  
- Enhance security and protection mechanisms of data transferred or exchanged to 
researchers outside Quebec  
- Educate the population regarding the scientific and ethical aspects of genetics and 
genetic research  
- Ensure public representation in organizations that financially support genetic 
research 
 
It is noteworthy that the Quebec’s Conseil de la Santé et du Bien Être has also released 
recommendations and suggestions to the government,  conclusions to which the 
Commission d’Accès à l’Information (CAI) has subscribed. These two institutions 
notably recommend for : (a) the establishment of an approbation  process for population 
biobanks that would involve the public (b) the creation of an independent institution 
accountable to the CAI (for instance) and responsible for the surveillance, accreditation 
and counselling of REBs as well as private and public organizations that collect, store 
and process human biological material and/or data, (c) provide financial support and 
adequate training opportunities to REBs and the CAI to ensure expertise and efficiency. 
Conseil de la Santé et du Bien-Être, L’Information génétique et l’accès à l’information 
des chercheurs : Il est urgent de protéger la population, (mémoire adopté par le Conseil 
de la Santé et du Bien-Être le 28 août 2003), Québec, 20 septembre 2003, 
http://www.ftsr.ulaval.ca/ethiques/memoire_cfr.pdf (Date accessed: 
February 24, 2005) 
Commission de l’Accès à l’Information, Une réforme de l’accès à l’information :le choix 
de la transparence, novembre 2002, 
http://www.cai.gouv.qc.ca/06_documentation/01_pdf/quin.pdf  
(Date accessed: February 24, 2005) 
Conseil de la Santé et du Bien-Être, La santé et le bien-être à l’ère de l’information 
génétique : enjeux individuels et sociaux à gérer, Québec, 2 février 2000, 
http://www.csbe.gouv.qc.ca/fr/publications/rapports/20000202_rapp_
cfr.pdf  (Date accessed: February 24, 2005) 
 
 
2) The elaboration of guiding principles by the Quebec Network of Applied 
Genetic Medicine (RMGA)  
 
Network of Applied Genetic Medicine (RMGA), Statement of Principles on the Ethical 
Conduct of Human Genetic Research Involving Population, Montréal, January 1, 2003, 
http://www.rmga.qc.ca/doc/ENONCE2002.ENG.pdf  (Date accessed: 
February 24, 2005) 
 
In the absence of a specific legal or ethical framework, the RMGA (an not-for–profit 
organization funded by the   Fonds de la Recherche en Santé du Québec) published its 
Statement of Principles on the Ethical Conduct of Human Genetic Research Involving 
Populations. This document, induced by the recent advances in genetics, genomics and 
bio-informatics, provides researchers guidance on the ethical and legal issues to be 
addressed when elaborating population biobanks ethical and governance framework.  
The fundamental principles that should govern population genetic research  are 
individuality, diversity, complexity, reciprocity, solidarity, security, accountability, 
equity, citizenry and universality. These principles should underlie the specific norms 
and standards pertaining to consultation, recruitment, consent, confidentiality, 
governance, research results communication, commercialization, and contribution to the 
well-being of society.  
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3) Federal ethical norms: updating existing ethical principles   
- The Tri-Council (Medical Research Council of Canada, Social Sciences and 
Humanities Research Council of Canada and Natural Sciences and Engineering 
Research Council of Canada) are currently updating their statement, notably its 
section 8 on human genetic research that is not adapted to the most recent scientific 
advances. The statement considers population biobanks to be one category of 
research to which additional rules apply rather than distinct research enterprises. 
However, it fails to take into consideration their specific features, ethical and 
governance challenges. The Tri-Council Policy Statement is applicable to all 
research funded by one of the three institutions.  
 
It is to be noted that these ethical principle must be applied by researchers financed by 
one of the three councils and can be voluntarily followed by other researchers. 
 
Medical Research Council of Canada, Natural Sciences and Engineering Research 
Council of Canada, Social Sciences and Humanities Research Council of Canada (IRSC, 
CRSNG et CRSH), Tri-Council Policy Statement — Ethical Conduct for Research 
Involving Humans 1998 (with 2000, 2002 updates), Ottawa, August 
1998, http://www.pre.ethics.gc.ca/english/pdf/TCPS%20June2003_E.p
df (Date accessed: February 24, 2005) 
 
- The Canadian Institutes for Health Research have published  a consultation draft of 
Best Practices in April 2004: Canadian Institutes for Health Research, Guidelines for 
Protecting Privacy and Confidentiality in the Design, Conduct and Evaluation of 
Health Research, Consultation Draft, Ottawa, April 2004, http://www.cihr-
irsc.gc.ca/e/pdf_22427.htm (Date Accessed: February 24, 2005) 
 
4)  The Federal Government : assuming a role in the delineation of principles  
 
The Canadian Biotechnology Advisory Committee has published an advisory 
memorandum in which it elaborates on the role the Federal Government has to play in 
the promotion of the Committee’s recommendations pertaining to population biobanks 
within the limits of its legislative competence. These recommendations address issues 
such as public education and engagement, privacy and confidentiality protection of 
research participants, recruitment and informed consent procedures (a balance between 
individual autonomy and freedom of research), benefit-sharing, and the elaboration of 
policies and best practices that promote such sharing, in collaboration with other levels 
of governments and interested parties. 
 
Canadian Biotechnology Advisory Committee, Genetic Research and Privacy - 
Advisory Memorandum, Ottawa, February 2004,  
http://cbac-cccb.ca/epic/internet/incbac-
cccb.nsf/vwapj/genetic_research_privacy.pdf/$FILE/genetic_research
_privacy.pdf (Date accessed: February 24, 2005) 
 
 
Denmark 
 
1) The sufficiency of the existing legal framework 
 
Working group composed of the Interior, Health, Science and Justice ministries, report 
2002, (Betaenkning no 1414, May 2002) (Information obtained from the European 
Commission website European Commission- Research Directorate General, Directorate 
E Biotechnology, Agriculture and Food, Survey on opinions from National Ethics 
Committees or similar bodies, public debate  and national legislation in relation to 
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human biobanks, Line Matthiessen (ed.), update October, 
http://www.europa.eu.int/comm/research/biosociety/bioethics/docum
ents_en.htm  (Date accessed: February 24, 2005) 
 
 
« The task group has assessed that the personal data act in interaction with the relevant 
legislation within health and research (The Act on the Legal Status of Patients an the Act 
on Science-Ethical Committee System Treatment of Bio-Medical Research Projects, Act 
on the Central Management of the Public Health Service, etc.., and other acts) does 
sufficiently regulates the majority of aspects of biobanks. (…) 
 
2) The need to amend certain provisions to take into consideration the specific 
features of « biobanks »  
 
“However, the task group does find that there is a need for new legislation in two areas: 
(1) Self-determination of biological material donated in connection with examination or 
treatment should be separately regulated by including new rules in the act on the 
legal status of patients. This will provide the patient with the opportunity to “back 
out” in relation to a central register; “The Register for Application of Tissue” with 
regard to non-treatment related application of donated biological material at the 
same time as the patient is given a right to destruction and a conditioned right to 
surrender donated biological material 
(2) It must be ensured that all research projects – also including register research 
projects – that incorporate biological material are notified to and approved by a 
science ethical committee. This will require an amendment of the act on science-
ethical committee system treatment of bio-medical research projects” 
 
3) The amendments of existing legislative provisions 
 
Le Danish legislator has adopted the recommendations made by the working group and 
amended accordingly two of its Acts in May 2005,  the Act on the Legal Status of 
Patients and the Act on Science-Ethical Committee System Treatment of Bio-Medical 
Research Projects. 
 
 
France 
 
1) The necessary harmonization of the legal status of biological material and its 
processing without unduly distinguishing between genetic and medical 
information.  
 
National Consultative Ethics Committee for Health and Life Science, Ethical Issues 
Raised by Collections of Biological Material and Associated Information Data : 
« Biobanks », « Biolibraries », Opinion No 77, Paris, March 20, 2003,  
http://www.ccne-ethique.fr/english/pdf/avis077.pdf  (Date accessed: 
February 24, 2005) 
 
« Firstly, there is a need to imagine a coherent framework to cover both the status of the 
physical elements collected and the rules governing the storing and the computerisation 
of the data. Genetic science must be reinstated within that system and not singled out for 
exceptional treatment (…). » (Report, II. 1. p.11) 
 
2) An imperfect legal framework 
 
«  In the French legal system, one point is clear. We are in a domain which legislators 
are intent on regulating. Neither the collection of elements, tissues, cells, etc. Of human 
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origin, nor the processing of the resulting information, are unregulated activities. Nor 
are they subject to the laws of marketable goods and services. On the contrary, several 
systems co-exist so that the same problems are approached form different angles which 
ignore each other. (…) The medley of legal approaches which could be applied to these 
collections in France, forms a miscellaneous assembly, containing references to various 
principles, and nevertheless leaving loopholes (…). » (Annex 1, p. 25)  
 
3) The recommendations of the National Consultative Ethics Committee (CCNE): 
the ethical principles that should govern “biobanks” or “biolibraries” 
 
The CCNE recommends the adoption of several ethical principles that would govern the 
collection, storing, use/processing of biological material and associated data. 
- It is of the responsibility of the State to harmonize the existing legal framework 
and institute a coherent and explicit status for biobanks and biolibraries. 
Transparency should be furthered 
- Collaboration between researchers and between researchers and banks as well as 
accountability mechanisms should be implemented. 
- The role, functions and obligations of the biobank’s curator or conservator should 
be defined  
- Consent requirements at the time of the collection of biological material and data, 
confidentiality and security of stored information should be strengthened 
-  The importance of the concept of solidarity should be acknowledged and the 
consultation of the French population ensured  
- The principle of the non-patrimonial nature of the human body should be 
respected and a reflection on the involvement of the private and public sector in 
research should be instigated 
- Benefit or advantages sharing policies should be considered 
 
4) The recent Loi relative à la bioéthique has amended several dispositions of the 
Code de la santé Publique taking into consideration the recommendations made 
by the CCNE: 
 
Loi no 2004-800 du 6 août 2004 relative à la bioéthique, Paris, 6 août 2004, J.O. no 182 
du 7 août 2004, p. 14040 texte no 1, 
http://www.admi.net/jo/20040807/SANX0100053L.html (Date accessed: 
February 24, 2005)  
 
Amendments made to the legal framework with regard to organs, tissues and cells and 
the collections composed of such biological material, more particularly Title 3 of the 
Act. Sont apportées au Code de la Santé Publique les modifications suivantes 
The following modifications to the Code de la Santé Publique are implemented as 
follow: 
-  Article L. 1131-4 specifies that the establishment of biological material 
collections when constituted for research purposes are regulated by articles L. 
1243-3 and L.1243-4  
- Article L. 1243-3 al.2 defines collections of biological materials as collections 
constituted for scientific purposes and containing biological samples (and 
associated data) collected from a group of identified individuals selected in light 
of the specific clinical or biological characteristics possessed by one or several 
members of this group.  
- An organisation wishing to create (process and store) such a biobank will have to 
be authorized to do so by either the Research Minister or the said Minister and 
the « agence territoriale  régionale d’hospitalisation » (Territorial and regional 
hospitalisation agency) if the organisation is an health establishment. This 
authorization can only be granted once the “Comité consultatif sur le traitement 
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de l’information en matière de recherche dans le domaine de la santé » ) 
(Consultative Committee on the Processing of Health Information for Research 
purposes) has expressed its opinion on the question. This Committee is 
established by virtue of article 40-2 Loi n 78-17 du 6 janvier 1978 relative à 
l’informatique, aux fichiers et aux libertés (article L. 1243-4). 
- L’ article L. 1243-3 states that, once this authorization obtained, the organization 
must declare its intention to constitute (and use) a collection of human biological 
material for research purposes. This declaration to be sent to the Research 
Minister as well as the territorial hospitalisation agency for health establishments 
must be preceded by an ethical and scientific evaluation of the research project 
undertaken by a competent REB. In the course of its ethical evaluation, the 
Committee will notably examine the contemplated consent procedure and  the 
information to be transmitted to the participants. (al. 1 et 3) 
- The Minister and agency, when applicable, upon receipt of the declaration can 
oppose it during a fixed period set by regulation. This opposition might be 
motivated by concerns regarding the safety of the professionals involved in the 
project, the protection of the environment, or the consent procedure and other 
ethical or scientific aspects of the project (article L. 1243-3 al. 4). 
These authorities can , likewise, put an end, suspend or forbid biobanking 
activities that do not respect ethical and scientific exigency and standards (article 
L. 1243-3 al. 5)This decision can only proceed once the “Comité consultatif sur 
le traitement de l’information en matière de recherche dans le domaine de la 
santé” has expressed its opinion on the matter. (article L. 1243-3 al. 6) 
 
 
Germany 
 
1) The need to elaborate a new regulatory scheme 
 
National Consultative Ethics Committee for Health and Life Science, Nationaler 
Ethikrat, Ethical Issues Raised by Collections of Biological Material and Associated 
Information Data : « Biobanks », « Biolibraries », Joint Document, 
http://www.ccne-ethique.fr/francais/pdf/avis077.pdf (Date accessed: 
February 24, 2005) 
 
« The analysis shows that, despite some differences, there is a need in both France and 
Germany, to elaborate a new regulatory framework covering collection, conservation, 
processing, and utilisation of the elements and data assembled in biobanks, and the 
development of research including protection of individuals. Since these activites are by 
no means restricted to national boundaries, efforts to achieve these ends must also be 
international » (at p. 40) 
 
2) The Opinion of the German National Ethics Council 
 
Nationaler Ethikrat, Biobanks for Research, Opinion, March 17, 2004, 
http://www.ethikrat.org/_english/publications/Opinion_Biobanks-for-
research.pdf  (Date accessed: February 24, 2005) 
« Few specific instruments and provisions exist concerning the handling of human 
bodily substances and personal data. It is clear from the international debate in the last 
ten years that biobanks present a variety of ethical, legal and social challenges. To 
tackle these, there is an evident need for a framework of new and consistent rules, 
particularly as cooperative projects involving researchers from different countries are 
increasingly likely. » (at p. 24) 
 
►► In its Opinion, the German National Ethics Council proposes 30 regulatory 
proposals that should guide the establishment and use of biobanks constituting of 
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biological material and associated data collected as part of care and to be secondarily 
used for research . The Council first defines biobanking activities and their current 
applications. It outlines their scientific value providing specific examples. Finally, the 
Council enunciates the guiding principles that Germany should edict for the scientific 
and ethical evaluation of biobanks, detailing the specific rules that should be 
implemented regarding the collection, storing, processing and use of information. The 
Opinion also proposes transitory  rules for « old » collections.  
 
 
U.K. 
 
1)   The scientific value of Biobanks  
 
Important public debate on the collection and storage of human tissues.  
 
Human Genetics Commission , Inside Information - Balancing Interests in the Use of 
Personal Genetic Data, London, May 1, 2002, 
http://www.hgc.gov.uk/insideinformation/index.htm (Date accessed: February 
24, 2005) 
- The Commission makes a number of recommendations to the government 
advocating the striking of an adequate balance between participants protection 
(privacy) and the advancement of science 
- Value of biobanks emphasized  
- The Commission recommends that an in-depth study of the issues specific to 
population biobanks be undertaken (notably issues such as consent, privacy and 
confidentiality protection, access, ownership). 
- The Commission advocates that biobanks for research be only used for research 
purposes, be supervised by an independent ethics board and an independent 
monitoring institution in order to ensure that such databases or collections are used 
in accordance with public wishes. The commission also promotes on-going public 
debate on the issues surrounding biobanks. 
-  
2) UK Biobank: the collaborative drafting of an ethics and governance framework  
 
UK Biobank Ethics and Governance Framework, Version 1.0, The Wellcome Trust, the 
Medical Research Council, the Department of Health, 24 September 2003, 
http://www.ukbiobank.ac.uk/documents/egf-comment-version.doc (Date 
accessed: February 24, 2005) Commented version. 
 
This framework discusses the specific issues and challenges population biobanks face while 
proposing solutions (open for comment). Among these issues the questions of governance 
(scientific monitoring, independent oversight by the Ethics and governance Council), consent 
requirements, data protection, accountability mechanisms or commercial aspects are 
analysed. 
 
3) UK Biobank Draft Policy on Intellectual Property and Access 
 
UK Biobank Policy on Intellectual Property (“IP”) and Access, Draft, London, January 11, 
2005, 
http://www.ukbiobank.ac.uk/docs/UKBiobankIPandAccesspolicyfirstpublic
draft11.1.5final2.pdf (Date accessed: February 24, 2005). 
 
In its draft policy, the UK Biobank specifies intellectual property and property rights in the 
resource as well as delineates the access rights of users and to samples or participants.   
 
According to this document, UK Biobank will be the steward and when permitted by law the 
(2005) vol. 3, no. 1, GenEdit, 1-13 
www.humgen.umontreal.ca/genedit 
Permission to reproduce granted if the source are correctly identified. ISSN 1718-9314 20
owner of the samples. Furthermore, with regard to access by users, the standards will differ 
depending on the nature of the material to be used: protected material, data in the public 
domain or non-proprietary material, or proprietary information. Access to protected material 
(i.e. data in an anonymized form about a participant including samples and data derived from 
these samples) will be allowed by application. It will be limited for research uses compatible 
with the bank’s purpose, scientifically and ethically approved by competent authorities, and 
in compliance of the Ethics and Governance and the participants’ consent.  
 
Access to data in the public domain comprised of findings and patent applications that have 
been published, and to data that though not in the public domain does not poses risks to 
participants should be openly accessible. However, discussions on this issue is on-going.  
 
Finally, access to proprietary data, i.e patented, will be controlled by the UK Biobank, 
watchdog of proprietors’ rights. The specific rules for such access will be determined at a 
later time.  
 
Turning to requests for access to samples or to re-contact participants for secondary purposes, 
these will be prioritised by the UK Biobank. The basis for such prioritisation will be 
determined by the UK Biobank’s Board of Directors, taking into consideration the Science 
Committee’s advice and after consultation of the Ethics and Governance Council on the 
issue. 
It is noteworthy that UK Biobank will only transfer physical samples to a researcher on an 
exceptional basis. In most cases a laboratory contracted out by UK Biobank will be 
responsible for the analysis, and access to the results will be granted to the researcher for use 
for a limited period of time. 
 
Finally, the draft policy also contains rules concerning fees for access, royalties, the 
dissemination of results and return of results as well as details regarding Access Agreements 
and Materials Transfer Agreements. 
 
 
 
Table 4 : Of some similarities and differences 
 
 Convergence – Consensus Divergence- controversial issues 
 
Consent 
 
- Adjusting traditional consent 
mechanisms to the specificity of 
biobanks  
 
 
- The width of the original 
consent to research and the 
secondary use of samples and 
data  
 
 
Privacy/Confidentiality 
 
- Correlation between the degree of 
data identifiability (anonymous, 
anonymized, double-coded, coded, 
identifiable) and the need to re-
contact participants, the possibility to 
withdraw from research, the question 
of results dissemination to 
participants and access to data by 
third parties  
-  
 
- Determining the adequate 
degree of identifiability 
- Access to data  
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Dissemination of 
results/information to 
participants 
 
- Requirement for exhaustive 
information prior to any large-scale 
population biobank 
 
- The right to know and not to 
know in the context of 
population biobanks : clinical 
interest, genetic counselling 
and interpretation of results  
 
 
Risks – discrimination 
 
- The need to take into account 
potential risks of discrimination not 
only at the time of recruitment but 
also when interpretating results  
 
 
- Information provided to 
participants on the risk of 
discrimination and  impacts 
on participation rate  
 
Governance and 
monitoring 
 
 
- The need for adequate  scientific and 
ethical oversight at the time of the 
biobank creation 
- On-going monitoring during the 
length of the project  
- Independence of the oversight 
institution, and  efficiency of its 
controls  powers including sanctions  
 
 
- Ethical oversight for 
international projects 
involving several countries: 
the nature of the control and 
bureaucratization of the  
- Governance : check and 
balances  
 
Public involvement 
 
- Promoting and reinforcing the 
dialogue between professionals and 
the public: the public as an active 
participant  
• In the drafting of the ethical 
and legal framework 
governing population 
biobanks 
• In the establishment of  each 
population biobanks project 
 
 
- Information, engagement, 
consent of the community or 
the population  
 
Commercial aspects 
 
- The need to elaborate benefit-sharing 
policies and to take into account the 
potential commercial uses of the data 
held in population projects resources 
 
 
- Financing such entreprises 
(public projects vs private or 
semi-private projects  
- The status of genetic 
material: ownership, 
participants , financial gains – 
beneficiaries  
- Involvement of private 
companies including the 
industry  
 
(2005) vol. 3, no. 1, GenEdit, 1-13 
www.humgen.umontreal.ca/genedit 
Permission to reproduce granted if the source are correctly identified. ISSN 1718-9314 22
                                                                  
 
                                                  
1 United Nations Educational, Scientific and Cultural 
Organization (UNESCO), International Bioethics 
Committee, International Declaration on Human 
Genetic Data, Paris, 16 October 2003, 
http://portal.unesco.org/en/ev.php-
URL_ID=17720&URL_DO=DO_TOPIC&URL_SECTIO
N=201.html (consulted 28 April 2005).  This declaration 
concerns “the collection, processing, usage and storage 
of human genetic data, human proteomic data and of 
the biological samples from which they are derived” 
article 1.  
2 Estonian Genome Project, 
http://www.geenivaramu.ee/index.php?show=main&lan
g=eng (consulted 28 April 2005). 
3 UK Biobank, http://www.ukbiobank.ac.uk (consulted 
28 April 2005). 
4 CARTaGENE, http://www.cartagene.qc.ca (consulted 
28 April 2005). 
5 GenomEUtwin, http://www.genomeutwin.org/  
(consulted 28 April 2005). 
6 Other populational databanks have equally been 
established around the world; an overview is provided 
by Dr. Anne Cambon-Thomsen in her article, Cambon-
Thomsen A., “The social and ethical issues of post-
genomic human biobanks,” (2004) 5 Nature Review 
Genetics 866-873; see also Institute national de la 
santé et la recherche médicale (INSERM), Les 
collections de ressources biologiques humaines (Coll. 
Repères) (Paris : INSERM, 2005) [only available in 
French]. 
7 Public Population Project in Genomics (P3G), 
http://p3gconsortium.org (consulted 28 April 2005). 
8 International Declaration on Human Genetic Data, 
supra note 1 art 2 (v). 
9 The Bioethics Advisory Committee of The Israel 
Academy of Sciences and Humanities, Population-
based large-scale Collections of DNA Samples and 
Databases of Genetic Information, Jerusalem, 
December, 2002, 
http://stwww.weizmann.ac.il/bioethics/PDF/Finalized_D
na_Bank_Full.pdf (consulted 28 April 2005) p. 1. 
10 Genetic exceptionalism consists of the conviction that 
genetic data require a greater degree of protection than 
other medical or personal data because of their genetic 
nature.  This attitude is largely linked to the assimilation 
of all genetic data to data predictive of serious, 
monogenic, and incurable diseases such as 
Huntington`s Disease.  McGee, G. “Foreward: genetic 
exceptionalism” (1998) 11 Harv J Law Technol 3:565-
570.      
11 Council for International Organizations of Medical 
Sciences (CIOMS), International Ethical Guidelines for 
Biomedical Research Involving Human Subjects, 
Geneva, November 1st 2002, 
http://www.cioms.ch/frame_guidelines_nov_2002.htm 
(date accessed: April 28, 2005).    
12 Council of Europe (CE), Convention for the 
Protection of Human Rights and Dignity of the Human 
Being with Regard to the Application of Biology and 
Medicine: Convention on Human Rights and 
Biomedicine, Oviedo, 4 April 1997, 
http://conventions.coe.int/Treaty/en/Treaties/Word/164.
doc (consulted 28 April 2005); Council of Europe, 
Additional Protocol to the Convention on Human Rights 
and Biomedicine, concerning Biomedical Research, 
Strasbourg, 25 January 2005, 
http://conventions.coe.int/Treaty/EN/Treaties/Html/195.
htm (consulted 28 April 2005). 
13 World Medical Association, The World Medical 
Association Declaration on Ethical Considerations 
Regarding Health Databases, Washington, 6 October, 
2002, http://www.wma.net/e/policy/d1.htm (consulted 
28 April 2005).  
14 International Declaration on Human Genetic Data, 
supra note 1. 
15 European Society of Human Genetics (ESHG), Data 
Storage and DNA Banking for Biomedical Research: 
Technical, Social and Ethical Issues, Birmingham, 
November 2001, (2003) 11 European Journal of Human 
Genetics   suppl. 2, S8-S10, 
 http://www.nature.com/ejhg/journal/v11/n2s/pdf/520111
5a.pdf (consulted 28 April 2005). 
16 World Health Organization,  Genetic Databases : 
Assessing the Benefits and the Impact on Human and 
Patient Rights, Geneva, 2003, 
http://www.law.ed.ac.uk/ahrb/publications/online/whofin
alreport.pdf, (consulted 28 April 2005).  
17 Human Genome Organization, Statement on Human 
Genomic Databases, London, December 2002, 
http://www.hugo-
international.org/Statement_on_Human_Genomic_Data
bases.htm (consulted 28 April 2005). 
18 United Nations Educational, Scientific and Cultural 
Organization (UNESCO), International Bioethics 
Committee, Universal Declaration on the Human 
Genome and Human Rights, Paris, 11 November, 
1997, http://portal.unesco.org/en/ev.php-
URL_ID=13177&URL_DO=DO_TOPIC&URL_SECTIO
N=201.html (consulted 28 April 2005). 
19 International Declaration on Human Genetic Data, 
supra note 1, article 1. 
20 The term “discrimination” evokes more the individual 
cases and the stimatization of groups. 
21Estonian Government, Human Genes Research Act, 
December 13, 2000, 
http://www.legaltext.ee/text/en/X50010.htm (consulted 
28 April 2005). 
22Human Genome Research Law, July 3, 2002, 
http://bmc.biomed.lu.lv/gene/print/Human%20Genome
%20Research%20Law,%20Latvia.doc  (unofficial 
translation of the “Biomedical Research and Study 
Centre”) (consulted 28 April 2005). 
23 Loi 96-452 du 28 mai 1996 portant diverses mesures 
d’ordre sanitaire, social et statutaire, J.O. no 123 du 29 
mai 1996 p. 7912, 
http://www.legifrance.gouv.fr/WAspad/UnTexteDeJorf?
numjo=TASX9500161L (consulted 28 April 2005), 
article 1 [available only in French]. 
24 Loi no 2004-800 du 6 août 2004 relative à la 
bioéthique, Paris, 6 août 2004, J.O. no 182 du 7 août 
2004, p. 14040 texte no 1, 
http://www.admi.net/jo/20040807/SANX0100053L.html 
(consulted 28 April 2005), especially the new article L. 
1131-4 of the Code de la santé Publique (CSP) 
introduced by title III of the law. 
25 Comité consultatif de bioéthique, supra note 9, 
paragraph 16. 
26 For example, the German National Ethics Council, le 
Nationaler Ethikrat, published an opinion on 17 March 
2004, “Biobanks for research.”  In this opinion, the 
Council proposed guidelines for biobanks destined for 
research and for those created by the collection of 
samples and of data within the medical domain but 
(2005) vol. 3, no. 1, GenEdit, 1-13 
www.humgen.umontreal.ca/genedit 
Permission to reproduce granted if the source are correctly identified. ISSN 1718-9314 23
                                                                   
which are afterwards used for research.  See Nationaler 
Ethikrat, “Biobanks for rsearch, Opinion,” 17 March 
2004, 
http://www.ethikrat.org/_english/publications/Opinion_Bi
obanks-for-research.pdf (consulted 28 April 2005). 
27 For a review of the terms used and a reflection on the 
taxonomic problems, see Knoppers B.M., Saginur 
M., “Toppling the Tower of Babel? Towards a Common 
Language for Biobanking” [Nature, forthcoming].  
28 Council for International Organizations of Medical 
Sciences, International Ethical Guidelines for 
Biomedical Research Involving Human Subjects, 
Geneva, November 1st 2002, 
http://www.cioms.ch/frame_guidelines_nov_2002.htm 
(date accessed: April 28, 2005), Introduction.    
29 UK Biobank Ethics and Governance Framework 
(Draft), http://www.ukbiobank.ac.uk/ethics/efg.php 
(consulted 28 April 2005). 
30 Human Genome Research Act, supra note 21, 
paragraphes 12(2), 16 and  22(7) ; see also Estonian 
Genome Project, “Gene Donor Consent Form”, 
http://www.geenivaramu.ee/index.php?lang=eng&sub=
74 (consulted 28 April 2005) page 11. 
31 European Commission, 25 Recommendations on the 
ethical, legal and social implications of genetic testing, 
Brussels, 2004, 
http://europa.eu.int/comm/research/conferences/2004/g
enetic/pdf/recommendations_en.pdf (consulted 28 April 
2005).   
32 International Declaration on Human Genetic Data, 
supra note 1, article 3 and 7.  
33 HapMap Project, 
http://www.hapmap.org/index.html.en  (consulted 28 
April 2005). 
34 United Nations Economic and Social Council, 
Information and comments received from Governments 
and relevant international organizations and functional 
commissions pursuant to Economic and Social Council 
resolution 2001/39 – Report of the Secretary General, 
Geneva, June 11, 2003, paragraph 30. 
http://daccessdds.un.org/doc/UNDOC/GEN/N03/395/67
/PDF/N0339567.pdf?OpenElement 
35 For an analysis of the emergence of these guiding 
principles, see Knoppers B.M., Chadwick R., “Human 
genetic Research: Emerging Trends in Ethics” (2005) 6 
Nature Review Genetics 75-79. 
36 Some impact measurement indices have begun to 
be envisaged:  Cambon-Thomsen A. Assessing the 
impact of biobanks. Nature Genetics (Correspondence), 
2003, 34, (1): 25-26.  
 
(2005) vol. 3, no. 1, GenEdit, 1-13 
www.humgen.umontreal.ca/genedit 
Permission to reproduce granted if the source are correctly identified. ISSN 1718-9314 24
